Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
R. Féty(Centre Hospitalier René-Dubos), G. Milano(Centre Antoine Lacassagne), Thierry Conroy(Inserm), G. Perrocheau, Jean‐Louis Merlin(Centre National de la Recherche Scientifique), M C Etienne, A. Riviére(Centre François Baclesse), F. Rolland(Institut de Cancérologie de l'Ouest), L. Campion(Centre National de la Recherche Scientifique), Agnès Hardouin(University Medical Center Utrecht), Muriel Barberi‐Heyob(Centre National de la Recherche Scientifique)
PubMed
September 1, 1998
Cited by 114
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k